Clik here to view.
拓臻生物将在2019美国肝病研究协会年会上发表FXR激动剂TERN-101临床前研究数据
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals...
View ArticleClik here to view.
Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young...
TOKYO Utilizing the capability of one’s own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved...
View ArticleClik here to view.
Terns Pharmaceuticalsが2019年米国肝臓学会議でFXR作動薬TERN-101の良好な前臨床データを発表へ
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Steven Rosenberg博士在癌症免疫治疗领域的成就激励日本的年轻研究人员，印度获奖人赢得第14届干细胞Fujio Cup Quiz
东京 (美国商业资讯)–利用个体自身免疫系统的功能来应对癌症，这一开箱即用的概念是约三十年前由Steven Rosenberg博士提出的。他的倡议为肿瘤学的新篇章铺平了道路，激励着日本东京召开的2019年度NCRM NICHE上的众多年轻科学家和临床工作者，他在江户川NICHE颁奖仪式上的获奖感言进行了视频直播。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted...
View ArticleClik here to view.
The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds...
PALM BEACH GARDENS, Fla. Xcovery Holdings, Inc., an oncology-focused biopharmaceutical company, today announced that ensartinib, the company’s lead drug candidate, demonstrated efficacy and safety...
View ArticleClik here to view.
がん免疫療法におけるスティーブン・ローゼンバーグ博士の偉業が日本の若い研究者の刺激に、幹細胞に関する第14回フジオカップクイズはインドのチームが優勝
東京 （ビジネスワイヤ） — 自己の免疫系が持つ能力を利用してがんと闘うという独創的なアイデアは、30年近く前にスティーブン・ローゼンバーグ博士が考案したものです。腫瘍学における新たな章の幕開けを告げた博士のイニシアチブは、東京で開催されたNCRM NICHE 2019で江戸川NICHE賞の受賞セレモニーにおける博士の受賞スピーチが上映された際に多くの若い科学者や臨床医に刺激を与えました。...
View ArticleClik here to view.
Solasia Announces Approval of episil® oral liquid in South Korea
TOKYO Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially...
View ArticleClik here to view.
Concept Medical的MagicTouch西罗莫司涂层产品组获得CE认证
荷兰荷佛拉肯 (美国商业资讯)–CE认证产品/品牌列表如下： 用于外周动脉疾病的MagicTouch – PTA（西罗莫司涂层PTA球囊导管） 用于勃起功能障碍的MagicTouch – ED（西罗莫司涂层球囊导管） 用于动静脉瘘和动静脉移植物内瘘的MagicTouch – AVF（西罗莫司涂层PTA球囊导管） MagicTouch –...
View ArticleClik here to view.
HiFiBiO Therapeutics Establishes World-Class Scientific Advisory Board
CAMBRIDGE, Mass. & SHANGHAI & PARIS HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, today announced...
View ArticleClik here to view.
Terns Pharmaceuticals Receives Fast Track Designation From the FDA for...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
拓臻生物宣布其非酒精性脂肪性肝炎(NASH)候选药物TERN-101获得美国FDA快速通道认证
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals 拓臻生物一家专注非酒精性脂肪性肝炎（NASH）和癌症创新疗法研发的全球生物制药公司，今天宣布其候选药物法尼醇X受体（FXR）激动剂TERN-101已获得美国食品和药物管理局（FDA）针对治疗NASH适应症的快速通道认证。 拓臻生物首席医学官Erin...
View ArticleClik here to view.
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014...
WALTHAM, Mass. Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the presentation of...
View ArticleClik here to view.
Terns Pharmaceuticals、NASH治療を目的とするFXR作動薬TERN-101に対するファストトラック指定をFDAより取得
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here:...
View ArticleClik here to view.
武田薬品：2019年度第2四半期の堅調な連結業績と通期業績予想の上方修正について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502) (NYSE:TAK)： 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20191030006223/ja/ 2019年度上期の実質的な売上収益は対前年同期△0.2％（Pro-forma2）...
View ArticleClik here to view.
All India Institute of Medical Sciences Finalizes the Biolog-id Transfusion®...
NEW DELHI Concluding the preliminary phase of a relationship started almost 18 months ago, AIIMS (New Delhi, India) and Biolog-id (Paris, France) have successfully completed a multi-phases...
View ArticleClik here to view.
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug...
NASHVILLE, Tenn. & TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today...
View ArticleClik here to view.
Quality Electrodynamics (QED) Sells Majority Ownership Interest to Canon Inc.
MAYFIELD VILLAGE, Ohio Quality Electrodynamics, LLC (QED), headquartered in Mayfield Village, Ohio, announced today the sale of 70% of its ownership interest to Canon Inc. (Canon) headquartered in...
View Article